A comparison between catalase and salivary alpha-amylase level in patients with type I diabetes and non-diabetic people

Abstract

The prevalence of diabetes and its complications encouraged the researchers to find effective ways with minimal side effects in order to diagnose and cure diabetes. The alphaamylase and catalase are salivary enzymes which could be effective in this area. The salivary alpha-amylase inhibitors reduce the absorption of complex carbohydrates and so are effective in the diagnosis of diabetes by controlling blood sugar and measurement of the concentration level of salivary alpha-amylase. Besides, the catalase deficiency is associated with oxidative effects of diabetes. The improvement in the level of catalase reduces the diabetes complications. Due to lack of studies and conflicting results regarding this topic, the present study aims to compare the level of catalase and salivary alpha-amylase in patients with diabetes type I with non-diabetic people. In the present descriptive analytic study, the unstimulated saliva belong to 40 patients affected by type 1 diabetes and 40 non-diabetic people was gathered. The amount of alpha-amylase and salivary catalase in diabetic and non-diabetic people was separately evaluated. The data obtained from the study was analyzed by descriptive analytical approaches. The T-test and SPSS.21 were also applied for independent groups. The average of salivary catalase enzyme was 447.9 آ± 143 KU/I in patients affected by diabetes and 283.7 آ± 229.7 KU/I in non-diabetic patients. The average of salivary alpha-amylase enzyme was 150075 آ± 158356.8 IU/mI in diabetic patients and 81825 آ± 66742.2 IU/mI in non-diabetic patients (p<0.05). The level of salivary alpha-amylase and catalase in people affected by type 1 diabetes was higher than the non-diabetic people.